Tetrahydrocurcumin compositions, methods of making, and methods of using the same
The present invention relates to novel tetrahydrocurcumin (THCu) compositions, novel methods of manufacturing, and methods of using these compositions for therapeutic applications. The novel synthetic pathway(s) result in THCu compositions that generally lack hexahydrocurcumin (HHC), and include an improved impurity profile with reduced additional species that are generally present in hydrogenated curcumin compositions.
1 . A parenteral composition comprising: a) tetrahydrocurcumin (THCu) according to the formula:
b) polyethylene glycol (PEG), and
c) a pharmaceutically acceptable excipient, wherein the composition lacks detectable amounts of hexahydrocurcumin (HHC) as indicated by no peak with a relative retention time (RTT) of 7.14-7.15 as determined by gas chromatography (GC).
2 . The parenteral composition of claim 1 , wherein the composition exhibits a peak associated with THCu at 9.07 for THCu as determined by GC.
3 . The parenteral composition of claim 2 , wherein the composition further comprises a peak at 8.23-8.25 RRT.
4 . The parenteral composition of claim 2 , wherein composition further comprises a peak at 2.75 RRT.
5 . The parenteral composition of claim 2 , wherein the pharmaceutically acceptable excipient is phosphatidylcholine.
6 . The parenteral composition of claim 1 , where the PEG has a molecular weight from 100 to 500.
7 . The parenteral composition of claim 6 , where the PEG has a molecular weight of 300.
8 . The parenteral composition of claim 1 , wherein the composition comprises between 0.1 to 1 wt % PEG.
9 . The parenteral composition of claim 8 , wherein the composition comprises of about 0.4 wt % PEG.
10 . A method of treating a disorder, wherein the method comprises administering to a patient in need thereof a pharmaceutical composition comprising tetrahydrocurcumin (THCu) according to the formula:
and
a pharmaceutically acceptable excipient, wherein the pharmaceutical composition lacks detectable amounts of hexahydrocurcumin (HHC) as indicated by no peak with a relative retention time of 7.14-7.15 as determined by GC.
11 . The method of claim 10 , wherein the composition exhibits a peak associated with THCu at 9.07 for THCu as determined by GC.
12 . The method of claim 10 , wherein the pharmaceutical composition further comprises a peak at 8.23-8.25 RRT.
13 . The method of claim 10 , wherein pharmaceutical composition further comprises a peak at 2.75 RRT.
14 . The method of claim 10 , wherein the pharmaceutically acceptable excipient is phosphatidylcholine.
15 . The method of claim 10 , wherein the pharmaceutical composition further comprises polyethylene glycol (PEG).
16 . The method of claim 15 , wherein the pharmaceutical composition comprises between 0.1 to 1 wt % PEG.
17 . The method of claim 16 , wherein the pharmaceutical composition comprises of about 0.4 wt % PEG.
18 . The method of claim 15 , wherein the PEG has a molecular weight from 100 to 500.
19 . The method of claim 18 , wherein the PEG has a molecular weight of 300.
20 . The method of claim 10 , wherein the disorder is selected from kidney disease, chronic kidney disease, or polycystic kidney disease.